Kitov Pharmaceuticals (KTOV) Getting Somewhat Favorable Press Coverage, Analysis Shows

News articles about Kitov Pharmaceuticals (NASDAQ:KTOV) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kitov Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.4047441585534 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Kitov Pharmaceuticals (NASDAQ:KTOV) traded down $0.02 on Thursday, reaching $2.34. The company’s stock had a trading volume of 113,400 shares, compared to its average volume of 168,150. Kitov Pharmaceuticals has a 52 week low of $1.27 and a 52 week high of $3.49.

Separately, HC Wainwright raised Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Tuesday, November 21st.

COPYRIGHT VIOLATION WARNING: “Kitov Pharmaceuticals (KTOV) Getting Somewhat Favorable Press Coverage, Analysis Shows” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3125852/kitov-pharmaceuticals-ktov-getting-somewhat-favorable-press-coverage-analysis-shows.html.

Kitov Pharmaceuticals Company Profile

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Insider Buying and Selling by Quarter for Kitov Pharmaceuticals (NASDAQ:KTOV)

Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.